

Giorgio G Galli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6893608/publications.pdf>

Version: 2024-02-01

22
papers

2,816
citations

471509

17
h-index

677142

22
g-index

26
all docs

26
docs citations

26
times ranked

6618
citing authors

#	ARTICLE	IF	CITATIONS
1	Hippo Pathway Activity Influences Liver Cell Fate. <i>Cell</i> , 2014, 157, 1324-1338.	28.9	683
2	Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening. <i>Cell</i> , 2017, 170, 577-592.e10.	28.9	506
3	The landscape of cancer cell line metabolism. <i>Nature Medicine</i> , 2019, 25, 850-860.	30.7	350
4	YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers. <i>Molecular Cell</i> , 2015, 60, 328-337.	9.7	228
5	PRDM proteins: Important players in differentiation and disease. <i>BioEssays</i> , 2012, 34, 50-60.	2.5	169
6	Yap reprograms glutamine metabolism to increase nucleotide biosynthesis and enable liver growth. <i>Nature Cell Biology</i> , 2016, 18, 886-896.	10.3	168
7	The Hippo Transducer YAP1 Transforms Activated Satellite Cells and Is a Potent Effector of Embryonal Rhabdomyosarcoma Formation. <i>Cancer Cell</i> , 2014, 26, 273-287.	16.8	152
8	Mammalian SWI/SNF continuously restores local accessibility to chromatin. <i>Nature Genetics</i> , 2021, 53, 279-287.	21.4	106
9	NUAK2 is a critical YAP target in liver cancer. <i>Nature Communications</i> , 2018, 9, 4834.	12.8	88
10	Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth. <i>EMBO Journal</i> , 2018, 37, .	7.8	73
11	PAX8 activates metabolic genes via enhancer elements in Renal Cell Carcinoma. <i>Nature Communications</i> , 2019, 10, 3739.	12.8	49
12	Prdm5 Regulates Collagen Gene Transcription by Association with RNA Polymerase II in Developing Bone. <i>PLoS Genetics</i> , 2012, 8, e1002711.	3.5	48
13	Genomic and Proteomic Analyses of Prdm5 Reveal Interactions with Insulator Binding Proteins in Embryonic Stem Cells. <i>Molecular and Cellular Biology</i> , 2013, 33, 4504-4516.	2.3	29
14	PAX8 and MECOM are interaction partners driving ovarian cancer. <i>Nature Communications</i> , 2021, 12, 2442.	12.8	29
15	Identification of the HECT E3 ligase UBR5 as a regulator of MYC degradation using a CRISPR/Cas9 screen. <i>Scientific Reports</i> , 2020, 10, 20044.	3.3	24
16	p190 RhoGAP promotes contact inhibition in epithelial cells by repressing YAP activity. <i>Journal of Cell Biology</i> , 2018, 217, 3183-3201.	5.2	21
17	A CRISPR-Cas9 screen identifies essential CTCF anchor sites for estrogen receptor-driven breast cancer cell proliferation. <i>Nucleic Acids Research</i> , 2019, 47, 9557-9572.	14.5	21
18	Systematic dissection of transcriptional regulatory networks by genome-scale and single-cell CRISPR screens. <i>Science Advances</i> , 2021, 7, .	10.3	19

#	ARTICLE	IF	CITATIONS
19	A role for repressive complexes and H3K9 di-methylation in PRDM5-associated brittle cornea syndrome. <i>Human Molecular Genetics</i> , 2015, 24, 6565-6579.	2.9	17
20	Therapeutic Assessment of Targeting ASNS Combined with <sc>l</sc>-Asparaginase Treatment in Solid Tumors and Investigation of Resistance Mechanisms. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 327-337.	4.9	13
21	Structure of the MRASâ€“SHOC2â€“PP1C phosphatase complex. <i>Nature</i> , 2022, 609, 416-423.	27.8	11
22	PAX8 lineage-driven T cell engaging antibody for the treatment of high-grade serous ovarian cancer. <i>Scientific Reports</i> , 2021, 11, 14841.	3.3	4